GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insur Regulatory News (SBRE)

Share Price Information for Sabre Insur (SBRE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 163.20
Bid: 163.20
Ask: 164.00
Change: -2.00 (-1.21%)
Spread: 0.80 (0.49%)
Open: 167.00
High: 167.00
Low: 163.20
Prev. Close: 165.20
SBRE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Oct 2018 07:00

RNS Number : 6525D
Sabre Insurance Group PLC
11 October 2018
 

11 October 2018

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2018.

Summary

· The Group continues its strategy of focusing on underwriting profitability over growth

· Superior underwriting performance, underpinned by strong claims experience in the period under review, supports the Group's continued expectation of delivering a FY 2018 combined ratio better than our mid-70%'s target and slightly higher than the FY 2017 combined ratio, which was 68.5%

· Strong organic capital generation supports the potential for an attractive full-year dividend with a solvency coverage ratio of 195%(1) as at the end of September, above our 140% - 160% target range

· Appropriate pricing actions taken to cover anticipated claims inflation, with GWP for the first nine months of the year remaining broadly flat year on year at £162.6m(1) (2017: £165.0m). The Group maintains its expectations for FY 2018 GWP to be in line with 2017

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of strong competition in the UK motor insurance sector, we have continued to apply our core philosophy of focusing on underwriting profitability, with volume remaining an output rather than target.

As communicated earlier in the year, we have sought to cover anticipated claims inflation and will continue this focus throughout the rest of this year. Whilst premiums for Q3 2018 were slightly below a strong comparative period in Q3 2017, we remain confident that we will end the year with premium in-line with 2017.

Our absolute focus on profitability has yielded a strong underwriting result for the year to date and has allowed us to generate significant excess capital during the period under review. Having paid an interim dividend of 7.2 pence per share, the solvency capital ratio as at 30 September 2018 is at 195%, well above our target operating range of 140%-160%. This provides the Board the option to return surplus capital to shareholders following the full-year results, should the capital position improve further throughout the remainder of 2018. 

(1) Numerical information not subject to audit

 

 

Media enquiries

Tulchan Communications LLP

James Macey White, Roger Tejwani & David Ison

020 7353 4200

sabre@tulchangroup.com

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood

adam.westwood@sabre.co.uk

07776 649 119

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFFUFISFASELS
Date   Source Headline
30th Mar 20211:56 pmRNSDirector/PDMR Shareholding
26th Mar 20218:24 amRNSDirector/PDMR Shareholding
16th Mar 20217:03 amRNSFinal Results
12th Mar 20217:00 amRNSNotice of Results
11th Mar 202110:37 amRNSDirector/PDMR Shareholding
1st Mar 20213:56 pmRNSHolding(s) in Company
23rd Feb 202110:40 amRNSNotice of Results
11th Feb 202110:28 amRNSDirector/PDMR Shareholding
1st Feb 202110:02 amRNSHolding(s) in Company
12th Jan 202110:53 amRNSDirector/PDMR Shareholding
8th Jan 20219:44 amRNSHolding(s) in Company
11th Dec 20201:31 pmRNSDirector/PDMR Shareholding
3rd Dec 20207:56 amRNSHolding(s) in Company
3rd Dec 20207:00 amRNSBoard Appointment
27th Nov 20204:42 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
11th Nov 202012:07 pmRNSDirector/PDMR Shareholding
6th Nov 202011:39 amRNSHolding(s) in Company
6th Nov 202010:55 amRNSHolding(s) in Company
27th Oct 20203:47 pmRNSDirector/PDMR Shareholding
15th Oct 20207:00 amRNSDirector/PDMR Shareholding
13th Oct 20209:42 amRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSTrading Statement
11th Sep 202010:07 amRNSDirector/PDMR Shareholding
3rd Sep 20204:13 pmRNSDirector/PDMR Shareholding
1st Sep 20202:23 pmRNSDirector/PDMR Shareholding
28th Aug 202012:02 pmRNSPrice Monitoring Extension
27th Aug 202011:32 amRNSDirector/PDMR Shareholding
19th Aug 20207:00 amRNSDirectorate Change
12th Aug 20203:50 pmRNSHolding(s) in Company
11th Aug 20201:15 pmRNSDirector/PDMR Shareholding
10th Aug 20204:00 pmRNSHolding(s) in Company
6th Aug 202012:14 pmRNSDirector/PDMR Shareholding - Correction
6th Aug 202010:11 amRNSDirector/PDMR Shareholding
6th Aug 20209:32 amRNSDirector/PDMR Shareholding
3rd Aug 202012:54 pmRNSDirector/PDMR Shareholding
28th Jul 20207:02 amRNSBoard appointment
28th Jul 20207:00 amRNSHalf-year Report
14th Jul 20204:13 pmRNSHolding(s) in Company
13th Jul 202012:51 pmRNSDirector/PDMR Shareholding
30th Jun 20201:33 pmRNSDirector/PDMR Shareholding
11th Jun 20201:59 pmRNSDirector/PDMR Shareholding
10th Jun 20209:57 amRNSDirector/PDMR Shareholding - Correction
4th Jun 20209:49 amRNSDirector/PDMR Shareholding
29th May 20203:39 pmRNSDirector/PDMR Shareholding
29th May 202012:37 pmRNSDirector/PDMR Shareholding
21st May 202012:17 pmRNSResult of AGM
21st May 20207:00 amRNSTrading Statement
13th May 20202:24 pmRNSDirector/PDMR Shareholding
12th May 202011:54 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.